Moreover, our functional work clearly shows that rendering the FOXM1 pathway inactive by RNAi knockdown or by use of the p19ARF 26-44 peptide [49], a selective FOXM1 peptide inhibitor called ARF, was highly effective in restoring endocrine sensitivity and suppressing breast cancer aggressiveness. Here, CDKN2A is linked to breast carcinoma.